LivaNova wins FDA approval for aura6000 sleep apnea device

CURRENT FULL VERSION: LivaNova’s aura6000 System has secured US FDA premarket approval for adults with moderate to severe obstructive sleep apnea, giving the company a long-awaited entry into the implantable sleep apnea device market. The approval, recorded by FDA on March 18, 2026, covers use in adults with an apnea-hypopnea index of 15 to 65 who have failed, don’t tolerate, or aren’t candidates for first-line treatment such as positive airway pressure. (accessdata.fda.gov)

This decision follows several years of clinical and regulatory work. LivaNova received FDA investigational device exemption approval in 2021 to begin its OSPREY study, a prospective, multicenter, randomized controlled trial evaluating the aura6000 in adults with moderate to severe OSA. The trial design randomized implanted participants 2:1 to active stimulation at month 1 or delayed activation at month 7, with the primary endpoint assessed at month 7. (businesswire.com)

The company’s regulatory case built in stages. In November 2024, LivaNova said OSPREY met its primary safety and efficacy endpoints at six months. By May 2025, it had completed its PMA submission and reported 12-month top-line data showing a 65% responder rate in the treatment arm, defined as at least a 50% improvement from baseline AHI and an AHI below 20. LivaNova also reported meaningful improvement in oxygen desaturation index, with 69% of treated patients achieving at least a 25% ODI reduction at month 7, versus 38% in controls. (investor.livanova.com)

What appears to set this approval apart is positioning. LivaNova says aura6000 is the first and only FDA-approved hypoglossal nerve stimulation therapy in the US without complete concentric collapse contraindication or warning language, and that implantation does not require pre-implant drug-induced sleep endoscopy. The system uses proximal hypoglossal nerve stimulation with six electrodes placed on the proximal trunk of the hypoglossal nerve, which the company says allows broader access to airway muscles and more titration options. Those claims come from the company, but they’re important because they point to a potential workflow and patient-selection distinction versus existing upper airway stimulation approaches. (markets.financialcontent.com)

Industry reaction has focused less on clinical controversy than on market implications. Medical Device Network reported that LivaNova is targeting a 2027 launch and sees the approval as a step toward commercial entry in a sizable OSA device category. Financial and market coverage also emphasized the competitive angle, especially the possibility that aura6000 could expand access by removing the complete concentric collapse limitation that has shaped candidate selection for other hypoglossal stimulation systems. In the background, FDA has also been signaling continued openness to newer implantable neuromodulation concepts beyond sleep medicine. One recent example is Nia Therapeutics’ Smart Neurostimulation System, which received Breakthrough Device Designation for episodic memory loss in adults with prior moderate to severe traumatic brain injury and persistent memory deficits. That fully implantable, closed-loop system is designed to record neural activity from 60 channels across four brain regions and deliver targeted stimulation to the lateral temporal cortex. According to company-reported data cited in trade coverage, it improved recall by 19% in a sham-controlled study of neurosurgical patients with epilepsy and a history of TBI, while random stimulation showed no benefit, and the company plans to file an IDE application in 2026. (medicaldevice-network.com)

Why it matters: For veterinary professionals, this isn’t a direct animal health regulatory event, but it is still useful context in a broader medtech sense. Neuromodulation platforms often evolve across indications, and FDA acceptance of another implantable nerve stimulation approach reinforces the durability of this device class. It also underscores how randomized controlled evidence is increasingly expected for premium implantable therapies. The parallel activity in other neurostimulation areas, including closed-loop systems being advanced under the FDA’s Breakthrough Device pathway, suggests the agency remains receptive to differentiated implantable brain and nerve interfaces when sponsors can show targeted, controlled clinical benefit. For clinicians and industry watchers, aura6000’s approval may be most notable for how it could reshape referral pathways, payer discussions, and procedural planning in human sleep medicine, especially if LivaNova’s claims around broader eligibility hold up in real-world use. (markets.financialcontent.com)

What to watch: The commercial product may not be the exact device now approved. LivaNova has said it is preparing a PMA supplement for a next-generation system designed to be MRI-compatible, remotely configurable, and rechargeable for up to 15 years, with launch expected in the first half of 2027 if FDA clears that supplement. The next milestones are likely to be supplement review, reimbursement and coverage discussions, and fuller publication of OSPREY outcomes beyond company summaries. In the wider neuromodulation field, another marker to watch will be whether programs such as Nia Therapeutics’ memory-loss system move from Breakthrough Device Designation into IDE-backed pivotal testing, which would further reinforce FDA support for increasingly sophisticated implantable neurostimulation platforms. (markets.financialcontent.com)